We are live on ! Find out more
DWTX

Dogwood Therapeutics

15 hedge funds and large institutions have $6.16M invested in Dogwood Therapeutics in 2026 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

15% more funds holding

Funds holding: 1315 (+2)

0.55% more ownership

Funds ownership: 10.84%11.39% (+0.55%)

19% less capital invested

Capital invested by funds: $7.64M → $6.16M (-$1.47M)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
15
Holders Change
+2
Holders Change %
+15.38%
% of All Funds
0.18%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
2
Reduced
3
Closed
3
Calls
Puts
Net Calls
Net Calls Change

DWTX Hedge Fund Activity: Q2 2026 in Review

15 of the 8,339 institutional investors tracked by Wall St. Rank reported a position in Dogwood Therapeutics (DWTX) for Q2 2026, worth a combined $6.16M — down 19% from $7.64M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new DWTX positions and 3 closed out — a net gain of 2 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $566K. The largest seller was Armistice Capital, cutting an estimated $244K.

  • 15 institutional investors held Dogwood Therapeutics (DWTX) as of Q2 2026, up from 13 in Q1 2026.
  • Funds reported $6.16M of Dogwood Therapeutics stock for Q2 2026, down 19% quarter-over-quarter.
  • 5 funds opened new Dogwood Therapeutics positions in Q2 2026 and 3 closed out, a net change of +2 holders.
  • The largest Dogwood Therapeutics buyer in Q2 2026 was Millennium Management, an estimated $566K added.
  • The largest Dogwood Therapeutics seller in Q2 2026 was Armistice Capital, an estimated $244K sold.

Based on aggregated 13F filings for Q2 2026.